Seres Therapeutics, Inc. Amortization of Debt Issuance Costs
Seres Therapeutics, Inc. (MCRB) reported Amortization of Debt Issuance Costs of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-12.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AmortizationOfFinancingCosts · last filed 2026-03-12
- Seres Therapeutics, Inc. amortization of debt issuance costs for the quarter ending 2025-12-31 was $0.00.
- Seres Therapeutics, Inc. amortization of debt issuance costs for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- Seres Therapeutics, Inc. amortization of debt issuance costs for the quarter ending 2025-06-30 was $0.00, a 100.00% decline year-over-year.
- Seres Therapeutics, Inc. amortization of debt issuance costs for the quarter ending 2025-03-31 was $0.00, a 100.00% decline year-over-year.
- Seres Therapeutics, Inc. amortization of debt issuance costs for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- Seres Therapeutics, Inc. amortization of debt issuance costs for fiscal 2024 was $1.41M, a 24.06% increase from fiscal 2023.
- Seres Therapeutics, Inc. amortization of debt issuance costs for fiscal 2023 was $1.14M, a 61.56% increase from fiscal 2022.
- Seres Therapeutics, Inc. amortization of debt issuance costs for fiscal 2022 was $705.00K, a 72.09% decline from fiscal 2021.
| Period end | Amortization of Debt Issuance Costs 3 month | Amortization of Debt Issuance Costs 6 month | Amortization of Debt Issuance Costs 9 month | Amortization of Debt Issuance Costs 12 month | Amortization of Debt Issuance Costs 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $0.00 derived: sum of 2 quarters · filed 2026-03-12 | $0.00 derived: sum of 3 quarters · filed 2026-03-12 | $0.00 10-K · filed 2026-03-12 | |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $0.00 derived: sum of 2 quarters · filed 2025-11-05 | $0.00 10-Q · filed 2025-11-05 | $0.00 derived: sum of 4 quarters · filed 2026-03-12 | |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $0.00 10-Q · filed 2025-08-06 | $0.00 derived: sum of 3 quarters · filed 2026-03-12 | $463.00K derived: sum of 4 quarters · filed 2026-03-12 | |
| 2025-03-31 | $0.00 10-Q · filed 2025-05-07 | $0.00 derived: sum of 2 quarters · filed 2026-03-12 | $463.00K derived: sum of 3 quarters · filed 2026-03-12 | $948.00K derived: sum of 4 quarters · filed 2026-03-12 | |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $463.00K derived: sum of 2 quarters · filed 2026-03-12 | $948.00K derived: sum of 3 quarters · filed 2026-03-12 | $1.41M 10-K · filed 2026-03-12 | |
| 2024-09-30 | $463.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $948.00K derived: sum of 2 quarters · filed 2025-11-05 | $1.41M 10-Q · filed 2025-11-05 | $1.82M derived: sum of 4 quarters · filed 2026-03-12 | |
| 2024-06-30 | $485.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $950.00K 10-Q · filed 2025-08-06 | $1.36M derived: sum of 3 quarters · filed 2026-03-12 | $1.75M derived: sum of 4 quarters · filed 2026-03-12 | |
| 2024-03-31 | $465.00K 10-Q · filed 2025-05-07 | $874.00K derived: sum of 2 quarters · filed 2026-03-12 | $1.27M derived: sum of 3 quarters · filed 2026-03-12 | $1.42M derived: sum of 4 quarters · filed 2026-03-12 | |
| 2023-12-31 | $409.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $802.00K derived: sum of 2 quarters · filed 2026-03-12 | $952.00K derived: sum of 3 quarters · filed 2026-03-12 | $1.14M 10-K · filed 2026-03-12 | |
| 2023-09-30 | $393.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $543.00K derived: sum of 2 quarters · filed 2024-11-13 | $730.00K 10-Q · filed 2024-11-13 | $882.00K derived: sum of 4 quarters · filed 2025-03-13 | |
| 2023-06-30 | $150.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $337.00K 10-Q · filed 2024-08-13 | $489.00K derived: sum of 3 quarters · filed 2025-03-13 | $714.00K derived: sum of 4 quarters · filed 2025-03-13 | |
| 2023-03-31 | $187.00K 10-Q · filed 2024-05-08 | $339.00K derived: sum of 2 quarters · filed 2025-03-13 | $564.00K derived: sum of 3 quarters · filed 2025-03-13 | $759.00K derived: sum of 4 quarters · filed 2025-03-13 | |
| 2022-12-31 | $152.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $377.00K derived: sum of 2 quarters · filed 2025-03-13 | $572.00K derived: sum of 3 quarters · filed 2025-03-13 | $705.00K 10-K · filed 2025-03-13 | |
| 2022-09-30 | $225.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $420.00K derived: sum of 2 quarters · filed 2023-11-02 | $553.00K 10-Q · filed 2023-11-02 | $2.71M derived: sum of 4 quarters · filed 2024-03-05 | |
| 2022-06-30 | $195.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $328.00K 10-Q · filed 2023-08-08 | $2.49M derived: sum of 3 quarters · filed 2024-03-05 | $2.61M derived: sum of 4 quarters · filed 2024-03-05 | |
| 2022-03-31 | $133.00K 10-Q · filed 2023-05-09 | $2.29M derived: sum of 2 quarters · filed 2024-03-05 | $2.42M derived: sum of 3 quarters · filed 2024-03-05 | $2.54M derived: sum of 4 quarters · filed 2024-03-05 | |
| 2021-12-31 | $2.16M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-05 | $2.29M derived: sum of 2 quarters · filed 2024-03-05 | $2.41M derived: sum of 3 quarters · filed 2024-03-05 | $2.53M 10-K · filed 2024-03-05 | $498.00K 10-K · filed 2022-03-01 |
| 2021-09-30 | $127.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-02 | $250.00K derived: sum of 2 quarters · filed 2022-11-02 | $368.00K 10-Q · filed 2022-11-02 | $590.00K derived: sum of 4 quarters · filed 2023-03-07 | |
| 2021-06-30 | $123.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03 | $241.00K 10-Q · filed 2022-08-03 | $463.00K derived: sum of 3 quarters · filed 2023-03-07 | ||
| 2021-03-31 | $118.00K 10-Q · filed 2022-05-04 | $340.00K derived: sum of 2 quarters · filed 2023-03-07 | |||
| 2020-12-31 | $222.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-07 | $551.00K 10-K · filed 2023-03-07 | $446.00K 10-K · filed 2021-03-02 | ||
| 2020-09-30 | $329.00K 10-Q · filed 2020-11-09 | ||||
| 2019-12-31 | $281.00K 10-K · filed 2022-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Context Therapeutics Inc. (CNTX) | United States | $0.034B | -1.10 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B |